Últimas publicaciones en anticoagulación
Bienvenido al Med Info Alert. En la siguiente página podrás encontrar información de interés sobre anticoagulación, publicada en los meses de marzo y abril.
ESUS
Del Brutto VJ, Diener HC, Easton JD, Granger CB, Cronin L, Kleine E, Grauer C, et al. Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. J Am Heart Assoc. 2022
Fibrilación Auricular y Anticoagulación
Hansen-Barkun C, Martel M, Douketis J, Abraham NS, Liederman Z, Kaplovitch E, Schulman S, et al. Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy. Am J Gastroenterol. 2023
Lip GYH, Tran G, Genaidy A, Marroquin P, Estes C, Landsheft J. Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: comparing common clinical risk scores and machine learning algorithms. Eur Heart J Qual Care Clin Outcomes. 2022
Patsiou V, Samaras A, Kartas A, Moysidis DV, Papazoglou AS, Bekiaridou A, Baroutidou A, et al. Prognostic implications of adherence to oral anticoagulants among patients with atrial fibrillation: Insights from MISOAC-AF trial. J Cardiol. 2023
Menichelli D, Pastori D, Pignatelli P, Pani A. Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. Eur Heart J Case Rep. 2023
Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, Fargo RA, et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022
Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry. EClinicalMedicine. 2022
Ding WY, Kotalczyk A, Boriani G, Marin F, Blomström-Lundqvist C, Potpara TS, Fauchier L, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. Eur J Intern Med. 2022
Bunch TJ, May H, Cutler M, Woller SC, Jacobs V, Stevens SM, Carlquist J, et al. Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial). J Arrhythm. 2022
Yan J, Liu M, Zhang Y, Yang D, An F. Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. Clin Cardiol. 2022
Bianchettin RG, Lavie CJ, Lopez-Jimenez F. Challenges in Cardiovascular Evaluation and Management of Obese Patients: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023
ICTUS ISQUÉMICO
Olthuis SGH, Pirson FAV, Pinckaers FME, Hinsenveld WH, Nieboer D, Ceulemans A, Knapen RRMM, et al; MR CLEAN-LATE investigators. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023
PRADAXA, PRAXBIND Y OTROS AGENTES REVERSORES
Romoli M, Matteo E, Migliaccio L, Gentile M, Mosconi MG, Scura GM, Naccarato M, et al. Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis. Eur Stroke J. 2023
Hitchcock ZR, Smith SD, Le LT, Lees LR, Brandt MD. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings. J Pharm Pract. 2023
MÁS PUBLICACIONES
PC-ES-110667